Table 23-12.

Quality of Care by Race/Ethnicity and Sex in the GWTG-HF Program, 2013

Quality-of-Care MeasureWhiteBlackHispanicMenWomen
Postdischarge appointment (new for 2011)*62.664.862.763.862.5
Complete set of discharge instructions94.395.295.294.894.1
Measure of LV function*99.499.399.399.499.2
ACEI or ARB at discharge for patients with LVSD, no contraindications*95.696.696.196.096.0
Smoking cessation counseling, current smokers96.395.796.096.195.6
Evidence-based specific β-blockers*89.292.089.290.689.3
β-Blockers at discharge for patients with LVSD, no contraindications97.898.298.398.097.9
Hydralazine/nitrates at discharge for patients with LVSD, no contraindications19.921.417.5
Anticoagulation for AF or atrial flutter, no contraindications81.379.076.381.779.3
Composite quality-of-care measure (using discharge instructions and β-blocker at discharge)96.897.097.196.896.6
  • Values are percentages. ACEI indicates angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; GWTG-HF, Get With The Guidelines−Heart Failure; LV, left ventricular; and LVSD, left ventricular systolic dysfunction.

  • * Indicates the 4 key achievement measures targeted in GWTG-HF.

  • Indicates historical key achievement measures in GWTG-HF.

  • For black patients only.